Neuroscientific Biopharmaceuticals Ltd
Research Neuroscientific Biopharmaceuticals Ltd (NSB) on Bullrun: market cap AUD 25.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNSB
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 25.33M
- Financial periodFY2025
- Net income-AUD 1.85M
- Free cash flow-AUD 941.33K
Valuation Snapshot
latest market cap is AUD 25.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 1.85M | -AUD 941.33K | n/a | -0.01 | AUD 7.27M | n/a | AUD 16.81M |
| FY2024 | n/a | AUD 324.21K | AUD 42.43K | n/a | 0 | AUD 9.20M | n/a | AUD 5.35M |
| FY2023 | n/a | -AUD 1.07M | -AUD 2.30M | n/a | -0.01 | AUD 4.91M | n/a | AUD 4.69M |
| FY2022 | n/a | -AUD 10.44M | -AUD 6.95M | n/a | -0.07 | AUD 7.22M | n/a | AUD 5.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 25.33M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neuroscientific Biopharmaceuticals Ltd's market cap?
Neuroscientific Biopharmaceuticals Ltd's market capitalization is AUD 25.33M.
What does Neuroscientific Biopharmaceuticals Ltd do?
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.